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Lichen planus (LP) is an uncommon disorder of unknown etiology mostly affecting women in their fifth and sixth 
decade of life. It is believed to be an autoimmune process 
involving T cells directed against basal keratinocytes, similar to 
graft-versus-host disease. It affects the skin, nails, oral pharynx, 
vulva and penis. Esophageal LP was first described in 1982 by 
Al-Shihabi and Jackson (1). LP involving the esophagus, stomach 
and rectum are rare. Esophageal LP can cause strictures, ulcera-
tions and squamous cell cancer. The present article describes a 
case of LP, including history, physical examination and endoscopic 
findings, as well as the different treatment options available.
CASE PRESENTATION
A 54-year-old woman with oral LP was referred for assessment 
of dysphagia at the Health Sciences Centre in St John’s, 
Newfoundland, in May 2005. In 2004, the patient suffered from 
dysphagia with solids and was diagnosed with pill esophagitis by 
the community gastroenterologist. However, her dysphagia pro-
gressed to soft foods but spared liquids. She was finally referred 
to our centre. She had lost 9.1 kg of body weight and had no 
reflux symptoms. Her medical history was remarkable for oral 
and vaginal LP, and pill esophagitis. She consumed alcohol 
socially and was a nonsmoker. Her family history consisted of a 
maternal uncle and aunt with colon cancer in their sixth decade 
of life. Her medications included tacrolimus 0.1% ointment 
twice daily and esomeprazole 40 mg daily.
First endoscopy
Her first endoscopy showed white plaques in the esophagus 
(Figures 1 and 2), which was quite narrow with strictures 
(Figure 3); therefore, advancing an adult endoscope was not 
possible. Candida was visible with the plaques. A biopsy 
revealed a dense lichenoid inflammatory infiltrate and candida 
yeast overgrowth (Figure 4).
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Lichen planus (LP) is an uncommon disorder of unknown etiology, 
mostly affecting patients in their fifth and sixth decade of life. It is 
believed to be an autoimmune process involving T cells directed 
against basal keratinocytes. It affects the skin, nails, oral pharynx and 
genitals. Esophageal involvement is quite rare and can cause strictures, 
ulcerations and squamous cell cancer. The present article describes the 
case of a 54-year-old woman who was referred for assessment of dys-
phagia that initially occurred with solids, which then progressed to soft 
foods but spared liquids. The patient reported a weight loss of 9.1 kg. 
An esophagogastroduodenoscopy was performed and she was subse-
quently diagnosed with pill esophagitis. At the same time, she was also 
diagnosed with oral LP, with no involvement of the esophagus. She 
was treated with a proton pump inhibitor that resolved her gastrointes-
tinal symptoms. The symptoms returned one year later and a repeat 
esophagogastroduodenoscopy revealed white plaques due to LP. She 
was treated with intermittent glucocorticoids. Diagnosis of esophageal 
LP is crucial for the proper treatment. Some patients may require sys-
temic immunosuppression and mechanical dilation to prevent weight 
loss. Surveillance endoscopies should be performed to monitor for 
squamous cell cancer. Cyclosporine has been used for genital and oral 
LP, but the present case is the first in which it has been used success-
fully to treat esophageal LP. 
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La cyclosporine dans la prise en charge du 
lichen plan œsophagien
Le lichen plan (LP) est un trouble peu fréquent à l’étiologie inconnue, qui 
touche surtout des patients dans la cinquantaine et la soixantaine. On 
pense qu’il s’agit d’un processus auto-immun mettant en cause les 
lymphocytes T, qui attaquent les kératinocytes basales. Il touche la peau, 
les ongles, le pharynx oral et les organes génitaux. L’atteinte œsophagienne 
est plutôt rare et peut provoquer des étranglements, des ulcérations et un 
carcinome spinocellulaire. Le présent article expose le cas d’une femme de 
54 ans qui avait été aiguillée pour subir une évaluation de dysphagie s’étant 
d’abord manifestée avec des solides, puis avait inclus les aliments mous, 
mais épargnait les liquides. La patiente a déclaré une perte de 9,1 kg. On 
lui a prescrit une œsophagogastroduodénoscopie, et elle a obtenu un 
diagnostic d’œsophagite piluleuse. Parallèlement, elle a reçu un diagnostic 
de LP oral, sans atteinte œsophagienne. Elle a été traitée au moyen 
d’inhibiteurs de la pompe à protons qui ont réglé ses symptômes gastro-
intestinaux. Les symptômes ont réapparu un an plus tard, et une nouvelle 
œsophagogastroduodénoscopie a révélé des plaques blanches imputables à 
un LP. Elle a reçu un traitement intermittent aux glucocorticoïdes. Le 
diagnostic de LP œsophagien est essentiel pour prescrire le bon traitement. 
Certains patients peuvent avoir besoin d’une immunosuppression 
systémique et d’une dilatation mécanique pour prévenir la perte de poids. 
Il faut procéder à des endoscopies de surveillance afin d’éviter l’apparition 
d’un cancer spinocellulaire. On a utilisé la cyclosporine pour traiter le LP 
génital et oral, mais il s’agit du premier cas où elle est utilisée avec succès 
dans le traitement du LP œsophagien.
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Second endoscopy
She was treated for candida esophagitis and underwent endos-
copy three months later. Endoscopy was performed with a 
pediatric gastroscope under fluoroscopy and revealed strictures 
with white plaques and friable mucosa.
REvIEW
LP is a ‘silent’ disease until the patient develops strictures and 
experiences dysphagia. The following will describe the usual 
findings involved in LP esophagitis. 
History and physical examination
Patients are usually asymptomatic; therefore, the incidence of 
esophageal LP is underestimated. Some patients may experi-
ence dysphagia due to strictures. Esophageal LP can also affect 
individuals with cutaneous LP – present as flat-topped, pruritic 
and violaceous papules or plaques in the flexural region of the 
arms, legs and wrists. Esophageal LP has a strong correlation to 
oral LP. Patients do not usually display symptoms of reflux dis-
ease. However, they are frequently mistaken to have 
gastroesophageal reflux disease and are treated without relief. 
Endoscopic findings
Endoscopy reveals proximal stricture formation, ulcers, granu-
lation tissue and inflammation in two-thirds of the esophagus. 
In addition, white, desquamating membranes with underlying 
friable mucosa can be found (Figure 5). The esophageal epi-
thelium is usually atrophic and shows parakeratosis.
DISCuSSION
Early and accurate diagnosis of esophageal LP is crucial because 
there is a potential risk for malignant transformation. Early 
diagnosis also helps initiate appropriate treatment and saves 
the patient from unnecessary dilation and weight loss. 
According to Shenfine and Preston (2), the risk of malignant 
transformation in patients with oral LP is 1% to 3%, and 0.5% 
to 1% according to Abraham et al (3). The actual malignant 
risk of esophageal LP is unknown and may mirror that of oral 
LP. To date, only three cases of squamous cell carcinoma arising 
from esophageal LP have been reported (4,5). Esophageal LP is 
Figure 1) Oral mucosal lesions, consistent with lichen planus
Figure 2) Esophageal lichen planus with Candida species yeast 
infection
Figure 3) Barium swallow showing decreased luminal calibre 
throughout the entire esophagus
Figure 4) Dense lichenoid inflammatory infiltrate underneath the 
lamina propria due to lichen planus. Civatte bodies are eosinophilic 
hyaline spherical bodies that are seen beneath the epidermis, particu-
larly in lichen planus
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under-reported because the symptoms are not always present. 
Dysphagia is common in symptomatic patients. LP tends to 
present in the proximal to mid esophagus. Because patients 
become uncomfortable when the endoscope approaches the 
epiglottis, there is a tendency to advance the endoscope quickly 
and miss oropharyngeal lesions, even by expert endoscopists. 
Treatment
Steroid therapy is the key treatment. Dilation of the strictures 
is believed to cause more damage via the Koebner phenom-
enon. However, if the patient is symptomatic and steroids do 
not act quickly enough, dilation can be performed. Retinoic 
acid has also been recommended for esophageal LP. Tacrolimus 
has been shown to be beneficial for the treatment of esopha-
geal LP (6). It is also used as a topical agent for the treatment 
of genital and oral LP. Cyclosporine has been used to treat 
genital LP (7). Antibacterial agents such as dapsone and 
immunosuppressants such as azathioprine have been used to 
treat only intractable cases of mucocutaneous LP (8,9). Unlike 
oral LP, esophageal LP cannot be treated with topical agents. 
Systemic agents are needed and relapse can occur once these 
agents are discontinued
CONCLuSION
Previous studies have shown that oral cyclosporine can be used 
successfully to treat oral LP (10). The present case is the first in 
which cyclosporine has been used successfully to treat esopha-
geal LP. 
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Figure 5) Esophageal lichen planus with friable mucosa
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